Drug Profile
Research programme: stapled peptide therapeutics - Aileron/Roche
Alternative Names: ATSP-7041; MDM2/MDMX dual inhibitor for p53-dependent cancers - Aileron/RocheLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Aileron Therapeutics; Roche
- Class Peptides
- Mechanism of Action Protein modulators; Proto-oncogene protein c mdm2 inhibitors; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Haematological malignancies; Inflammation; Metabolic disorders; Solid tumours; Viral infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA